Insmed (NASDAQ:INSM) CEO William Lewis Sells 19,215 Shares

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 19,215 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. The trade was a 5.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

William Lewis also recently made the following trade(s):

• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $4.00 during mid-day trading on Tuesday, reaching $163.72. 3,740,754 shares of the company traded hands, compared to its average volume of 3,000,077. The company’s 50 day moving average price is $189.67 and its 200-day moving average price is $152.98. The firm has a market cap of $34.92 billion, a PE ratio of -26.45 and a beta of 1.08. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the previous year, the business posted ($1.27) EPS. Insmed’s revenue was up 52.4% on a year-over-year basis. On average, equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on INSM. Leerink Partners reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. The Goldman Sachs Group upped their price objective on Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Redburn Partners set a $263.00 target price on Insmed in a research report on Thursday, December 4th. Bank of America boosted their price target on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Finally, Evercore ISI restated an “outperform” rating and issued a $180.00 price target on shares of Insmed in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $205.77.

Institutional Trading of Insmed

Hedge funds have recently modified their holdings of the company. CIBC Private Wealth Group LLC increased its position in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. ORG Partners LLC increased its holdings in shares of Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 196 shares during the last quarter. Hilltop National Bank purchased a new stake in shares of Insmed during the 2nd quarter valued at about $28,000. Stone House Investment Management LLC purchased a new stake in shares of Insmed during the 3rd quarter valued at about $29,000. Finally, SBI Securities Co. Ltd. lifted its holdings in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.